Technology ID
TAB-5001
Genetically Modified Bdellovibrio and E. coli Strains for Advancing Antibiotic Resistance Research and Drug Development
E-Numbers
E-197-2014-0
Lead Inventor
Nabel, Gary
Lead IC
NIAID
Co-Inventors
Olshevsky, Udy
Leung, Kwanyee
ICs
NIAID
Applications
Therapeutics
Research Materials
Therapeutic Areas
Infectious Disease
Development Stages
Pre-Clinical (in vitro)
Research Products
Plasmids/Vectors
This technology includes genetically modified strains of Bdellovibrio and E. coli bacteria, along with associated plasmids, that have been engineered for antibiotic resistance. These modified bacterial strains and plasmids have been developed to replace specific genes with antibiotic resistance markers, allowing for more precise studies in genetic research, as well as the development and testing of new antibiotics. The potential use of this technology lies in enhancing research on antibiotic resistance mechanisms and facilitating the creation of novel therapeutic approaches to combat resistant bacterial infections.
Commercial Applications
This technology can be applied in research laboratories for studying the genetic mechanisms of antibiotic resistance, helping scientists understand how resistance develops and spreads. It also has potential applications in the pharmaceutical industry for screening and developing new antibiotics that can overcome resistance in pathogenic bacteria.
Competitive Advantages
This technology offers a competitive advantage by providing precisely engineered bacterial strains with antibiotic resistance, enabling more accurate and controlled studies of resistance mechanisms. Additionally, it facilitates the development and testing of new antibiotics, potentially accelerating the discovery of effective treatments for resistant bacterial infections.
Licensing Contact: